Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 4/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826120 | 0.89 | PYCR1 (0.45) | PYCR1MAOBKDM4EALDH1A1CXCR3 | |
| SCHEMBL16327151 | 0.83 | PYCR1 (0.50) | PYCR1CXCR3LSS | |
| SCHEMBL4267535 | 0.81 | CXCR3 (0.41) | MAOBALDH1A1CXCR3LSS | |
| SCHEMBL17887960 | 0.81 | PYCR1 (0.51) | PYCR1CXCR3TAAR1 | |
| SCHEMBL14045705 | 0.81 | ALDH1A1 (0.52) | PYCR1MAOBKDM4EALDH1A1 | |
| SCHEMBL12215364 | 0.80 | PYCR1 (0.50) | PYCR1MAOBKDM4EALDH1A1CXCR3 | |
| SCHEMBL15128047 | 0.80 | PYCR1 (0.67) | PYCR1MAOBKDM4EALDH1A1CXCR3 | |
| SCHEMBL12891100 | 0.79 | EP300 (0.47) | PYCR1CXCR3LSS | |
| SCHEMBL26668497 | 0.78 | EP300 (0.46) | CXCR3LSS | |
| SCHEMBL8283980 | 0.75 | ALDH1A1 (0.46) | PYCR1MAOBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | PYCR1 258/4885MAOB 3894/4885KDM4E 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.